Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer

Breast Cancer Research and Treatment

Volumn 97, Issue 3, 2006, Pages 245-254

  Dignam, James J ^a,d   Wieand, Kelly ^a   Johnson, Karen A ^b   Raich, Peter ^c   Anderson, Stewart J ^d,e   Somkin, Carol ^f   Wickerham, D Lawrence ^g  

^a UNIVERSITY OF CHICAGO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d NSABP Foundation Inc   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f DIVISION OF RESEARCH   (United States)

^g ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Black women; Competing risks; Estrogen receptor negative; Obesity; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE;

AFRICAN AMERICAN; ARTICLE; BODY MASS; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CAUSE OF DEATH; COMORBIDITY; DISEASE FREE SURVIVAL; EUROPEAN AMERICAN; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; RECURRENCE RISK; SECOND CANCER; STATISTICAL MODEL;

ADULT; AFRICAN AMERICANS; ANTINEOPLASTIC AGENTS; BODY MASS INDEX; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; MULTICENTER STUDIES; NORTH AMERICA; OBESITY; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 33745479842     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9118-3     Document Type: Article

References (52)

1. Chlebowski RT, Aiello E, McTiernan A: Weight loss in breast cancer patient management. J Clin Oncol 20: 1128-1143, 2002
2. Verreault R, Brisson J, Deschenes L, Naud F: Body weight and prognostic indicators in breast cancer. Modifying effect of estrogen receptors. Am J Epidemiol 129: 260-268, 1989
3. Jain M, Miller AB: Tumor characteristics and survival of breast cancer patients in relation to premorbid diet and body size. Breast Cancer Res Treat 42: 43-55, 1997
4. Cui Y, Whiteman MK, Flaws JA, Langenberg P, Tkaczuk KH, Bush TL: Body mass and stage of breast cancer at diagnosis. Int J Cancer 98: 279-283, 2002
5. Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas E: Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early stage breast cancer. J Natl Cancer Inst 95: 1467-1476, 2003
6. Lee CW, Norris B, Moravan V, Olivotto I: Does body mass index influence the effectiveness of adjuvant tamoxifen in postmenopausal women with early stage breast cancer? Breast Cancer Res Treat 82: S71, 2003
7. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Erien D, Collins J, Snyder R, Thurlimann B, Fey MF, Mendiola C, Werner ID, Simoncini E, Crivellari D, Gelber RD, Goldhirsch A: Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group Experience. Ann Oncol 15: 874-884, 2004
8. Maehle BO, Tretli S: Pre-morbid body-mass-index in breast cancer: reversed effect on survival in hormone receptor negative patients. Breast Cancer Res Treat 41: 123-130, 1996
9. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY: Re: reversal of relation between body mass and endogenous estrogen concentrations with menopausal status (letter). J Natl Cancer Inst 89: 396-398, 1997
10. Potischman N, Swanson CA, Siiteri P, Hoover RN: Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 88: 756-758, 1996
11. Elledge RM, Clark GM, Chamness GC, Osborne CK: Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 86: 705-712, 1994
12. Chen VW, Correa P, Kurman R, Wu XC, Eley JW, Austin D, Muss H, Hunter CP, Redmond C, Sobhan M: Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev 3: 127-135, 1994
13. Elmore JG, Moceri VM, Carter D, Larson EB: Breast carcinoma tumor characteristics in black and white women. Cancer 83: 2509-2515, 1998
14. Chu KC, Anderson WF, Fritz A: Frequency distributions of breast cancer characteristics classified by estrogen and progesterone receptor status for eight racial/ethnic groups. Cancer 92: 37-45, 2001
15. Anderson WF, Chatterjee N, Ershler WB, Brawley OW: Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76: 27-36, 2002
16. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288: 1723-1727, 2002
17. Jones BA, Kasl SV, Curnen MG, Owens PH, Dubrow R: Severe obesity as an explanatory factor for the black/white difference in stage at diagnosis of breast cancer. Am J Epidemiol 146: 394-404, 1997
18. Moorman PG, Jones BA, Millikan RC, Hall IJ, Newman B: Race, anthropometric factors, and stage at diagnosis of breast cancer. Am J Epidemiol 153: 284-291, 2001
19. Roach M III, Cirrincione C, Budman D, Hayes D, Berry D, Younger J, Hart R, Henderson IC: Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. Cancer J Sci Am 3: 107-112, 1997
20. Cross CK, Harris J, Recht A: Race, socioeconomic status, and breast carcinoma in the U.S.: what have we learned from clinical studies? Cancer 95: 1988-1999, 2002
21. Chu KC, Lamar CA, Freeman HP: Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment. Cancer 97: 2853-2860, 2003
22. Dignam JJ, Redmond CK, Fisher B, Costantino J, Edwards BK: Prognosis among African-American women and white women with lymph node negative breast carcinoma: findings from two randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). Cancer 80: 80-90, 1997
23. Dignam JJ: Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women. J Natl Cancer Inst Monogr 30: 36-43, 2001
24. Fisher B, Redmond C, Dimitrov NV, Bowman D, Legault-Poisson S, Wickerham DL, Wolmark N, Fisher ER, Margolese R, Sutherland C: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 320: 473-478, 1989
25. Fisher B, Dignam J, Mamounas EP, Costantino J, Wickerham DL, Redmond C, Wolmark N, Dimitrov NV, Bowman D, Glass AG, Atkins JN, Abramson N, Sutherland C, Aron B, Margolese RG: Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 14: 1982-1992, 1996
26. Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG, Farrar WB: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19: 931-942, 2001
27. United States Department of Health and Human Services. The Surgeon General's call to action to prevent and decrease overweight and obesity. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General, 2001. http://www.surgeongeneral.gov/ topics/obesity/calltoaction/CalltoAction.pdf [Accessed October 11, 2005]
28. Remington RD: Who should code cause of death in a clinical trial? Control Clin Trials 5: 241-244, 1984
29. Korn EL, Dorey FJ: Applications of crude incidence curves. Stat Med 11: 813-829, 1992
30. Prentice RL, Kalbfleisch JD, Peterson AV, Flournoy N, Farewell VT, Breslow NE: The analysis of failure times in the presence of competing risks. Biometrics 34: 541-554, 1978
31. Sauerbrei W, Royston P, Bojar H, Schmoor C, Schumacher M: Modeling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG). Br J Cancer 79: 1752-1760, 1999
32. Katzmarzyk PT, Janssen I, Ardern CI: Physical inactivity, excess adiposity and premature mortality. Obes Rev 4: 257-290, 2003
33. Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, Schilsky RL: Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from Cancer and Leukemia Group B study 8541. J Clin Oncol 14: 3000-3008, 1996
34. Madarnas Y, Sawka CA, Franssen E, Bjarnason GA: Are medical oncologists biased in their treatment of the large woman with breast cancer? Breast Cancer Res Treat 66: 123-133, 2001
35. Lyman GH, Dale DC, Crawford J: Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21: 4524-4531, 2003
36. Dignam JJ, Mamounas EP: Obesity and breast cancer prognosis: an expanding body of evidence (editorial). Ann Oncol 15: 850-851, 2004
37. Willett WC, Browne ML, Bain C, Lipnick RJ, Stampfer MJ, Rosner B, Colditz GA, Hennekens CH, Speizer FE: Relative weight and risk of breast cancer among premenopausal women. Am J Epidemiol 22: 731-740, 1985
38. van den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom AR, Fraser G, Goldbohm RA, Graham S, Kushi L, Marshall JR, Miller AB, Rohan T, Smith-Warner SA, Speizer FE, Willett WC, Wolk A, Hunter DJ: Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152: 514-527, 2000
39. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, Noguchi S: Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9: 5699-5704, 2004
40. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, Lupu R: Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 101: 10,715-10,720, 2004
41. Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, Hennekens CH, Rosner B, Speizer FE, Willett WC: Dual effects of weight and weight gain on breast cancer risk. JAMA 278: 1407-1411, 1997
42. Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW: Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat 81: 21-31, 2003
43. Hershman H, McBride R, Jacobson JS, Lamerato L, Roberts K, Grann V, Neugut AI: Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 23: 6639-6646, 2005
44. Albain KS, Unger JM, Hutchins LF, Rivkin SE, Martino S, Livingston RB, Osborne CK: Outcomes of African Americans on Southwest Oncology Group (SWOG) breast cancer adjuvant therapy trials. Breast Cancer Res Treat 82: S12, 2003
45. Jones BA, Kasl SV, Howe CL, Lachman M, Dubrow R, Curnen MM, Soler-Vila H, Beeghly A, Duan F, Owens P: African American/white differences in breast carcinoma: p53 and other tumor characteristics. Cancer 101: 1293-1301, 2004
46. Porter PL, Lund MJ, Lin MG, Yuan X, Liff JM, Flagg EW, Coates RJ, Eley JW: Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 100: 2533-2542, 2004
47. Newman LA, Bunner S, Carolin K, Bouwman D, Kosir MA, White M, Schwartz A: Ethnicity related differences in the survival of young breast carcinoma patients. Cancer 95: 21-27, 2002
48. Mehrotra J, Ganpat MM, Kanaan Y, Fackler MJ, McVeigh M, Lahti-Domenici J, Polyak K, Argani P, Naab T, Garrett E, Parmigiani G, Broome C, Sukumar S: Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res 10: 2052-2057, 2004
49. Goodwill PJ, Ennis M, Pritchard KI, McCready D, Koo J, Sidlofsky S, Trudeau M, Hood N, Redwood S: Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol 17: 120-129, 1999
50. Demark-Wahnefried W, Peterson BL, Winer EP, Marks L, Aziz N, Marcom PK, Blackwell K, Rimer BK: Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patient receiving adjuvant chemotherapy. J Clin Oncol 19: 2381-2389, 2001
51. Irwin ML, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Gilliland FD, Ballard-Barbash R: Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 23: 774-782, 2005
52. Kroenke CH, Chen WY, Rosner B, Holmes MD: Weight, weight gain and survival after breast cancer. J Clin Oncol 23: 1370-1378, 2005